{'52WeekChange': -0.530478,
 'SandP52WeekChange': 0.0644362,
 'address1': '60 Binney Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 64.14,
 'askSize': 900,
 'averageDailyVolume10Day': 681050,
 'averageVolume': 1325190,
 'averageVolume10days': 681050,
 'beta': 2.353501,
 'beta3Year': None,
 'bid': 64.15,
 'bidSize': 900,
 'bookValue': 20.144,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 64.76,
 'dayLow': 63.1916,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.439,
 'enterpriseToRevenue': 52.986,
 'enterpriseValue': 2864751616,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 64.28915,
 'fiftyTwoWeekHigh': 141,
 'fiftyTwoWeekLow': 38.95,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 55376076,
 'forwardEps': -12.12,
 'forwardPE': -5.3003297,
 'fromCurrency': None,
 'fullTimeEmployees': 1153,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0061799996,
 'heldPercentInstitutions': 1.0996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/bluebirdbio.com',
 'longBusinessSummary': 'bluebird bio, Inc., a clinical-stage biotechnology '
                        'company, focuses on developing transformative gene '
                        'therapies for severe genetic diseases and cancer. Its '
                        'product candidates in severe genetic diseases include '
                        'LentiGlobin, which is in various clinical studies for '
                        'the treatment of transfusion-dependent '
                        'Ã\x9f-thalassemia and severe sickle cell disease; and '
                        'Lenti-D that is in Phase II/III clinical trials for '
                        'the treatment of cerebral adrenoleukodystrophy, a '
                        "rare hereditary neurological disorder. The company's "
                        'product candidates in oncology include bb2121 and '
                        'bb21217, which are chimeric antigen receptor T (CAR '
                        'T) cell product candidates for the treatment of '
                        'multiple myeloma. It has a strategic collaboration '
                        'with Celgene Corporation to discover, develop, and '
                        'commercialize disease-altering gene therapies in '
                        'oncology; and Regeneron Pharmaceuticals, Inc. to '
                        'discover, develop, and commercialize various immune '
                        'cell therapies for cancer. The company also has '
                        'collaborations with Medigene AG to discover T cell '
                        'receptor (TCR) product candidates in the field of '
                        'cancer; Gritstone Oncology, Inc. to discover TCR '
                        'product candidates in the field of cancer; TC '
                        'BioPharm Limited to research and develop gamma delta '
                        'CAR T cells directed at hematologic and solid tumor '
                        'targets; and Novo Nordisk A/S to develop in vivo '
                        'genome editing treatments for genetic diseases. The '
                        'company was formerly known as Genetix '
                        'Pharmaceuticals, Inc., and changed its name to '
                        'bluebird bio, Inc. in September 2010. bluebird bio, '
                        'Inc. was founded in 1992 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'bluebird bio, Inc.',
 'market': 'us_market',
 'marketCap': 3575090688,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_28921',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -827772992,
 'nextFiscalYearEnd': 1640908800,
 'open': 64.66,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.16,
 'phone': '339-499-9300',
 'previousClose': 65.26,
 'priceHint': 2,
 'priceToBook': 3.189039,
 'priceToSalesTrailing12Months': 66.124565,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 64.76,
 'regularMarketDayLow': 63.1916,
 'regularMarketOpen': 64.66,
 'regularMarketPreviousClose': 65.26,
 'regularMarketPrice': 64.66,
 'regularMarketVolume': 449505,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 55652100,
 'sharesPercentSharesOut': 0.1321,
 'sharesShort': 7349303,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7594325,
 'shortName': 'bluebird bio, Inc.',
 'shortPercentOfFloat': 0.21049999,
 'shortRatio': 6.35,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'BLUE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -14.955,
 'twoHundredDayAverage': 65.89094,
 'volume': 449505,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.bluebirdbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}